GlassScriptPhysician profile
Amy Wood
NPI 1619944188
$8,101.63
in general payments reported to CMS, 2019-2025
25 companies · $2,633 in 2025
The $2,633 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $438 · 2021: $386 · 2022: $796 · 2023: $1,300 · 2024: $1,630 · 2025: $2,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,483 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,483.26 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,285.29 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,194.10 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $943.17 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $655.51 | 2019-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $608.62 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $572.62 | 2019-2025 | |
| Amgen INC. | $515.89 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $506.08 | 2021-2025 | Opzelura |
| Ucb, INC. | $390.93 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $381.94 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $228.21 | 2023-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $215.59 | 2019-2020 | |
| Galderma Laboratories, L.P. | $171.13 | 2019-2025 | Oracea, Aklief, Nemluvio |
| Arcutis Biotherapeutics, INC. | $160.19 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $44.03 | 2025 | Anzupgo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $42.94 | 2023 | |
| Epi Health, LLC | $41.98 | 2021-2022 | |
| Sebela Pharmaceuticals INC. | $29.73 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.68 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2024 | Cyltezo |
| Verrica Pharmaceuticals INC. | $14.24 | 2025 | Ycanth |
| Allergan, INC. | $12.12 | 2019 | |
| Mission Pharmacal Company | $11.04 | 2021 | |
| Organon LLC | $6.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.